Genomic newborn screening as a paradigm shift in rare disease management, with emphasis on endocrine conditions
DNA sequencing newborn screening can detect rare genetic diseases before symptoms emerge, enabling treatment to prevent permanent organ damage in vulnerable infants.
This expert consensus review from the French National Rare Diseases Network describes how NGS-based newborn screening — from targeted gene panels to WES and WGS — represents a transformative paradigm shift for rare endocrine disease management, enabling pre-symptomatic intervention before irreversible organ damage. The integration into France's national Genomic Medicine 2025 plan signals near-term clinical implementation at scale.
What the study was
- Study design
- Expert review from French National Rare Diseases Network (FIRENDO), multicenter framework
- Population
- Newborns; rare endocrine disease populations; France national program
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Annales d'Endocrinologie
Why it surfaced
National program-level implementation of genomic newborn screening; FIRENDO expert consensus; direct applicability to rare endocrine disease populations with high unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.